{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:56:19Z","timestamp":1790834179449,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00277-014-2229-3","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T01:30:45Z","timestamp":1413163845000},"page":"375-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation"],"prefix":"10.1007","volume":"94","author":[{"given":"Maya","family":"Koren-Michowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Maayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Apel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Shem-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Volchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"issue":"2","key":"2229_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/2040620711402533","volume":"2","author":"K James","year":"2011","unstructured":"James K, Mangan SML (2011) Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol 2(2):73\u201382. doi: 10.1177\/2040620711402533","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"2229_CR2","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VHJ Velden van der","year":"2001","unstructured":"van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJM (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10):3197\u20133204. doi: 10.1182\/blood.V97.10.3197","journal-title":"Blood"},{"issue":"6","key":"2229_CR3","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490\u20131496","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2229_CR4","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1200\/JCO.2009.26.7930","volume":"28","author":"K Filanovsky","year":"2010","unstructured":"Filanovsky K, Shvidel L, Shtalrid M (2010) Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia. J Clin Oncol 28(7):e115\u2013e116. doi: 10.1200\/JCO.2009.26.7930 , author reply e117-8","journal-title":"J Clin Oncol"},{"issue":"6","key":"2229_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","volume":"50","author":"J Cortes","year":"2002","unstructured":"Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50(6):497\u2013500","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2229_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","volume":"51","author":"Y Alvarado","year":"2003","unstructured":"Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ (2003) Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87\u201390","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2229_CR7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","volume":"27","author":"E Apostolidou","year":"2003","unstructured":"Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27(10):887\u2013891","journal-title":"Leuk Res"},{"issue":"10","key":"2229_CR8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(03)00022-5","volume":"27","author":"A Tsimberidou","year":"2003","unstructured":"Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893\u2013897","journal-title":"Leuk Res"},{"issue":"9","key":"2229_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.leukres.2004.01.009","volume":"28","author":"PP Piccaluga","year":"2004","unstructured":"Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, Baccarani M (2004) First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 28(9):987\u2013990","journal-title":"Leuk Res"},{"issue":"6","key":"2229_CR10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00277-007-0272-z","volume":"86","author":"G Specchia","year":"2007","unstructured":"Specchia G, Pastore D, Carluccio P, Spinosa G, Giannoccaro M, Rizzi R, Mestice A, Liso V (2007) Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 86(6):425\u2013428","journal-title":"Ann Hematol"},{"issue":"32","key":"2229_CR11","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau J-L (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 26(32):5192\u20135197. doi: 10.1200\/jco.2007.15.9764","journal-title":"J Clin Oncol"},{"issue":"3","key":"2229_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2010.07.017","volume":"35","author":"RM Stone","year":"2011","unstructured":"Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: cancer and leukemia group B study 19902. Leuk Res 35(3):329\u2013333","journal-title":"Leuk Res"},{"issue":"4","key":"2229_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajh.23653","volume":"89","author":"S Pilorge","year":"2014","unstructured":"Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terr\u00e9 C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P (2014) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55\u00a0years with acute myeloid leukemia in late first relapse. Am J Hematol 89(4):399\u2013403. doi: 10.1002\/ajh.23653","journal-title":"Am J Hematol"},{"issue":"1","key":"2229_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","volume":"30","author":"AD Cohen","year":"2002","unstructured":"Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30(1):23\u201328","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2229_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncponc0899","volume":"4","author":"T Owonikoko","year":"2007","unstructured":"Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A (2007) Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol 4(8):491\u2013495","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"2229_CR16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.leu.2405029","volume":"22","author":"H Tamai","year":"2007","unstructured":"Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T, Nakayama K, Inokuchi K, Tajika K, Dan K (2007) Treatment of relapsed acute myeloid leukemia with MLL\/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Leukemia 22(6):1273\u20131274","journal-title":"Leukemia"},{"issue":"5","key":"2229_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12185-009-0440-0","volume":"90","author":"M Sumi","year":"2009","unstructured":"Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H (2009) Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Int J Hematol 90(5):643\u2013647. doi: 10.1007\/s12185-009-0440-0","journal-title":"Int J Hematol"},{"issue":"2","key":"2229_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1620\/tjem.220.121","volume":"220","author":"T Ando","year":"2010","unstructured":"Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y (2010) Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med 220(2):121\u2013126. doi: 10.1620\/tjem.220.121","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"2229_CR19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12185-011-0967-8","volume":"94","author":"T Tachibana","year":"2011","unstructured":"Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H (2011) Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation. Int J Hematol 94(6):580\u2013582. doi: 10.1007\/s12185-011-0967-8","journal-title":"Int J Hematol"},{"issue":"11","key":"2229_CR20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.bmt.1705852","volume":"40","author":"DA Pollyea","year":"2007","unstructured":"Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K (2007) Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 40(11):1027\u20131032","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2229_CR21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bmt.2008.255","volume":"42","author":"BE Shaw","year":"2008","unstructured":"Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42(12):783\u2013789","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2229_CR22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721\u2013727","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2229-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2229-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2229-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:49:55Z","timestamp":1559022595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2229-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2229-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}